AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04651868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CCK
Description: A 180 mins intravenous infusion with cholecystokinin (0.4 pmol × kg\^-1 × min\^-1)
Study NCT04651868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A 180 mins intravenous infusion with isotonic NaCl
Study NCT00607087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Description: 100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
Study NCT00607087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Description: 100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
Study NCT00607087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: 100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
Study NCT01824550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home-based exercise training condition
Description: Home based endurance exercise training
Study NCT00779493 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: curcumin
Description: curcumin 900mg twice daily by mouth
Study NCT00779493 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule to simulate 900mg curcumin capsule
Study NCT01648972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gastrografin
Study NCT01648972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03612336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS (vaporizer/e-cig) and smoking cessation counseling
Description: Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
Study NCT03612336 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation counseling
Description: Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
Study NCT00748098 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo
Study NCT00104858 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo HSCT
Study NCT00104858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO
Study NCT03148353 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subacromial injection
Description: 1. Modified ultrasound guided corticosteroid subacromial injection~2. Standardized ultrasound guided corticosteroid subacromial injection
Study NCT03148353 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Subacromial injection
Description: 1. Modified ultrasound guided corticosteroid subacromial injection~2. Standardized ultrasound guided corticosteroid subacromial injection
Study NCT04506034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine patches
Description: for every port entry site from the three in ports of laparoscope, patients received three lidocaine patches 5% (Lidoderm® , Endo Pharmaceuticals, Chadds Ford, PA). Each patch measured 10 cm × 14 cm and contains (700 mg), was divided into two equal parts, six parts applied two of it around one port entry site that marked before sterilization and just before induction of anesthesia. The patches not changed until removed after return of bowel function or on the maximum at fifth postoperative day.
Study NCT04506034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV lidocaine
Description: received i.v. lidocaine infusion after induction of anesthesia, 2 mg/min if body weight >70 kg or 1 mg/min if body weight \<70 kg.
Study NCT04506034 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV saline infusion
Description: received i.v. saline infusion.
Study NCT02845557 — intervention group
Intervention type: OTHER
Intervention: OGTT and IVGTT tests
Study NCT04869046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Instillation of levobupivacaine in surgical wound
Description: Once the hernia tissue had been surgically managed, the wound was sutured in layers and a solution of 0.5% levobupivacaine, 0.5 mg/kg (0.1 ml/kg), was instilled into the wound of children in the experimental group before suturing of the abdominal fascia. That same amount of 0.9% saline was given to children in the control group. The absorption of the solution took approximately 3 minutes, after which the wound was sutured. After completion of wound suturing, all children received 20 mg/kg of paracetamol administered as a rectal suppository.
Study NCT05581459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 63 Hz Vibration
Description: Vibrations of 63 Hz were applied with handheld vibration device.
Study NCT00104858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT00104858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT05581459 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 42 Hz Vibration
Description: Vibrations of 42 Hz were applied with handheld vibration device.
Study NCT05581459 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham vibration
Description: Handheld device was applied to the participants without any vibrations.
Study NCT00104858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO
Study NCT00104858 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo HSCT
Study NCT03615950 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Height measurement
Description: Height will be measured at baseline and 12 months.
Study NCT03615950 — intervention group
Intervention type: OTHER
Intervention: Assessment of medication compliance
Description: Subjects enrolled in the intervention group will undergo assessment of compliance with swallowed corticosteroids prescribed by their clinical provider. This will be performed at 6 and 12 months.
Study NCT02822508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI801 Laxative
Description: BLI801 oral laxative
Study NCT03384940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8201a
Description: DS-8201a is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration
Study NCT03827525 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cognitive and Behavioral Therapy
Description: 9 sessions of Cognitive and Behavioral Therapy will be realised with the patient by a clinical psychologist. They will last between 1h and 1h30.
Study NCT00104858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00104858 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT00104858 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT04869046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Instillation of levobupivacaine in surgical wound
Description: Once the hernia tissue had been surgically managed, the wound was sutured in layers and a solution of 0.5% levobupivacaine, 0.5 mg/kg (0.1 ml/kg), was instilled into the wound of children in the experimental group before suturing of the abdominal fascia. That same amount of 0.9% saline was given to children in the control group. The absorption of the solution took approximately 3 minutes, after which the wound was sutured. After completion of wound suturing, all children received 20 mg/kg of paracetamol administered as a rectal suppository.
Study NCT00550407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lamotrigine
Description: lamotrigine 100mg/day or 200mg/day
Study NCT00557154 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: ultrasound used to identify target vein
Study NCT04109768 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutrition and activity
Description: 16 sessions; nutrition 8; activity 8- 45 minutes to improve health and nutrition literacy
Study NCT00550407 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo once daily
Study NCT04593524 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D 1000 IU and A 6000 IU supplementation and nutritional counseling
Description: 24 participants, which are treatment group (I) which receives nutritional counseling, vitamin D 1000 IU, vitamin A 6000 IU
Study NCT04593524 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nutritional Counseling
Description: control group (C) which only receives nutritional counseling for 28 days
Study NCT02504489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel + Plinabulin (DP)
Description: Docetaxel 75 mg/m2 IV + Plinabulin 30 mg/m2
Study NCT02504489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel (D)
Description: Docetaxel 75 mg/m2 IV
Study NCT02504489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel (D)
Description: Docetaxel 75 mg/m2 IV
Study NCT01815827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inclacumab
Description: single intravenous doses
Study NCT01815827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inclacumab
Description: single intravenous doses
Study NCT02418052 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neck flexion
Description: After the cervical esophagogastric anastomoses is completed and the skin incision is closed, the patient's occiput will be lifted, and then the neck will be maintained in flexing position by an assistant. The underside of the chin will be fixed to the anterior chest wall with two stout nylon sutures by the surgeon. The neck will be fixed in the neutral flexing position for 7 to 10 days after surgery.
Study NCT03766126 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART123 cells; cyclophosphamide; fludarabine
Description: CART123 cells following lymphodepleting chemotherapy in patients with relapsed/refractory AML. Subjects will be treated with a split dosing approach of CART123 cells (10% Day 0; 30% Day 1; 60% Day 2) for Cohort 1a/1b or a single IV administration of CART123 cells for Cohort 2.~The total dose administered to each subject will be based on body weight obtained at the time of apheresis. Thus, the target total transduced dose, preceded by lymphodepleting chemotherapy, is 1-2x10\^6 CART123 cells/kg for Cohort 1a, 5x10\^6 CART123 cells/kg for Cohort 1b, or 2x10\^6 CART-123 cells/kg for Cohort 2. The protocol-specified minimum acceptable dose for infusion is 1x10\^5 CART123 cells/kg.
Study NCT01006759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise and orientation
Description: guidances for prevention of disability in leprosy with focus on hands, eyes and feet.
Study NCT04444466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB8600
Description: Study participants will receive UCB8600 in a pre-specified sequence during the Treatment Period.
Study NCT04444466 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants will receive Placebo in a pre-specified sequence during the Treatment Period matching UCB8600.
Study NCT02053090 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Education and Stretching
Study NCT02053090 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group Acupuncture
Study NCT01434849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical 0.5% Timolol maleate
Description: topical 0.5% Timolol aqueous solution, 1-2 drops to cover the hemangioma, twice daily
Study NCT01434849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control (placebo) group
Description: Aqueous placebo, 1-2 drops to cover the hemangioma, twice daily
Study NCT02203994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Duolith® SD 1 T-Top (Storz Medical AG, Switzerland)
Description: 2000 pulses per muscle, energy level: 0.030 mJ/mm2, frequency: 4 Hz
Study NCT00063778 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVX101
Description: Alphavirus replicon particle vaccine expressing HIV Gag antigen
Study NCT00063778 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: phosphate buffered saline, pH 7.2, HSA, sodium gluconate, and sucrose
Study NCT01288989 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-3C5
Description: Escalating doses of IMC-3C5 administered intravenously (i.v.), weekly or every other week
Study NCT00921349 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ligation of varices
Description: all varices are ligated until obliteration
Study NCT00921349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadolol
Description: Nadolol (beta-blocker)
Study NCT00921349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nadolol
Description: Nadolol (beta-blocker)
Study NCT02160054 — intervention group
Intervention type: DRUG
Intervention: Graceptor®
Description: oral
Study NCT02515734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Study NCT02515734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT02515734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Study NCT01551238 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Differences in protein content of meals
Description: Differences in protein content (energy percent) of meals
Study NCT02515734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Study NCT02822508 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BLI801 Placebo
Description: BLI801 oral laxative placebo
Study NCT02515734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan
Study NCT02515734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Study NCT02515734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Study NCT02515734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study NCT04135638 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cover Group
Description: Cover when the ILM flap is everted over the MH gap in a single layer
Study NCT04135638 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fill Group
Description: Fill when the ILM is folded into multiple layers within the MH
Study NCT00347152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divalproex
Description: Divalproex, 8-20% taper
Study NCT02515734 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Study NCT02515734 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Study NCT03449719 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT - Ablative radiation Therapy
Description: The current phase II randomized trial,Ablative Radiation Therapy in patients with Oligometastatic castration resistant prostate cancer (ARTO trial) aims to evaluate the difference in PSA response rate between the experimental arm (AA+SBRT) and control arm (AA) in metastatic castration-resistant prostate cancer patients.
Study NCT03449719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone Acetate
Description: systemic treatment with abiraterone acetate 1000 mg daily and prednisone 10 mg daily, plus GnRH agonist or antagonist
Study NCT03449719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: systemic treatment with abiraterone acetate 1000 mg daily and prednisone 10 mg daily, plus GnRH agonist or antagonist
Study NCT03642509 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left atrial appendage occlusion
Description: Interventional left atrial appendage occlusion with the Amulet or Watchman device
Study NCT03642509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOAC
Description: Medical treatment arm. Patients will be treated with one of the available NOAC drugs; Apixaban, Dabigatran, Edoxaban or Rivaroxaban. The specific drug and dose is at the discretion of the treating physician.
Study NCT03201419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 201836
Description: Oral solution for daily intake
Study NCT03201419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: Desmopressin Orally Disintegrating Tablet (ODT)
Study NCT03201419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral solution
Description: Manufactured to mimic experimental drug
Study NCT03201419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ODT
Description: Manufactured to mimic experimental drug
Study NCT04181346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: antipsychotic
Study NCT04181346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT01259180 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture treatment
Description: twice a week, 6 weeks, 12sessions penetrating skin with stailess steel acupuncture device(diameter: 0.25-0.3mm,legth: 30-70mm) points: BL 23,BL31,BL32, BL40, BL53, GB30, SP 6 bilaterally plus Ashi. with
Study NCT01259180 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham acupunture
Description: twice a week, 6 weeks, 12 sessions not penetrating skin with dull acupuncture device(Park Sham device :Acuprime Co. Ltd, UK) point: 1\~2inches away from real acupuncture point
Study NCT03025984 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Texting
Description: patient adherence to her recommended care regimen after intervention of a text message reminder and education system
Study NCT02825615 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radial artery cannulation
Description: Radial artery cannulation done with conventional and ultrasound guidance in two respective groups of patients and their first pass success and ultimate success rates compared in different hemodynamic subsets of the patients.
Study NCT02825615 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radial artery cannulation
Description: Radial artery cannulation done with conventional and ultrasound guidance in two respective groups of patients and their first pass success and ultimate success rates compared in different hemodynamic subsets of the patients.
Study NCT01458483 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baroreceptor Stimulation
Description: The stimulation catheter may be placed in different locations within the IJV at the level of the cervical spine vertebrae. Stimulation amplitudes will be varied from 0.1 mA to 20 mA.
Study NCT01200303 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non-cathartic CTC
Description: non-cathartic, CAD-assisted CT Colonography
Study NCT01817504 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Systematic transplantectomy
Description: Transplantectomy within two months after return to dialyse. Antiproliferatives stop at the start of dialysis. Maintenance basic immunosuppressive treatment without dose reduction up to two weeks after transplantectomy. Abrupt discontinuation of the basic immunosuppressive treatment ttwo weeks after transplantectomy. Maintenance corticosteroids at 5mg per day until one month after transplantectomy then stop corticosteroids within one month.
Study NCT01817504 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Progressive reduction of immunosuppression
Description: Progressive reduction of immunosuppression. Transplantectomy for cause only. Antiproliferatives withdrawn at the start of dialysis. Maintenance of anticalcineurin or mTOR inhibitors half dose for 3 months, ¼ dose for 3 months and then stop. Maintenance corticosteroids for 6 months up to 5 mg per day, and then soft stop in 3 months.~In case of transplantectomy by reason in the control group, basic immunosuppression will be continued at the maintenance dose during the current surgical procedure, and withdrawn two weeks later, similary to the strategy used in the study group.
Study NCT04266132 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anaesthesia
Description: General anaesthesia will be induced with 8% sevoflurane in oxygen and maintained with 1 MAC sevoflurane via a laryngeal mask.